

CURRICULUM VITAE

Annie Wong-Beringer, PharmD

PERSONAL INFORMATION

| | |
|--------------------|--|
| Business Address | University of Southern California School of Pharmacy 1985 Zonal Avenue Los Angeles, CA 90089-9121 |
| Business Telephone | (626) 397-3059, (323) 442-1356 |
| Business FAX | (626) 628-3024 |
| E-mail Address | anniew@usc.edu |

ACADEMIC CREDENTIALS

| | |
|---------|---|
| 1983-86 | University of California Irvine, School of Biological Sciences, Irvine, California |
| 1986-90 | Pharm.D. University of Southern California, School of Pharmacy, Los Angeles, California |

POSTGRADUATE EDUCATION

| | |
|---------|--|
| 1990-91 | Residency Certificate Resident in Clinical Pharmacy University of California, School of Pharmacy San Francisco, California |
| 1991-92 | Fellowship Certificate Fellow in Infectious Diseases University of California, School of Pharmacy San Francisco, California |

LICENSURE

| | |
|--------------|--|
| 1990-Present | California State Board of Pharmacy RPH ——— |
|--------------|--|

ACADEMIC APPOINTMENTS

- 2003 present **Associate Professor of Clinical Pharmacy**
University of Southern California, School of Pharmacy
Los Angeles, California
- 1997 - 2003 **Associate Professor of Pharmacy Practice, Tenured**
Western University of Health Sciences
College of Pharmacy
Pomona, California
- 1994 - 1996 **Assistant Clinical Professor of Pharmacy**
University of California, School of Pharmacy
San Francisco, California
- 1992 - 1993 **Assistant Professor of Clinical Pharmacy**
University of Southern California, School of Pharmacy
Los Angeles, California

NON-ACADEMIC PROFESSIONAL APPOINTMENTS

- 1997 - Present **Infectious Diseases Pharmacist Specialist**
Huntington Memorial Hospital
Pasadena, California
- 1993 - 2001 **Competency Committee Member (Appointed, 8-year term)**
California State Board of Pharmacy
- 1993 - 1996 **Infectious Diseases Pharmacist Specialist**
UCLA Medical Center
Los Angeles, California
- 1991 - 1992 **Fellow in Infectious Diseases**
University of California, School of Pharmacy
San Francisco, California
- 1990 - 1991 **Resident in Clinical Pharmacy**
University of California, School of Pharmacy
San Francisco, California
- 1986 - 1990 **Intern Pharmacist**
Presbyterian Intercommunity Hospital
Whittier, California
- 1988 - 1990 **Intern Pharmacist**
Sav-On Drugs
Arcadia, California

TEACHING ACTIVITY

Didactic

Course Coordinator & Lecturer – 2004, 2005
Infectious Diseases Therapeutics Module I (PHRD 605),
University of Southern California, School of Pharmacy

Course Coordinator, Lecturer – 1997 to 2003
Infectious Diseases Block, Western University, College of Pharmacy

Pharm.D. Student Clerkship

Infectious Diseases Elective Rotation – 1999 to present

Postgraduate Training Preceptorship

Infectious Disease Residency/Fellowship – 1993 to present

Student Research Projects Supervised

- 1999-00 _____, Pharm IV: Prospective evaluation of levofloxacin use at a community teaching hospital
- _____ , Pharm IV: Implementation of an IV to oral antimicrobial conversion program.
- _____ , Pharm IV: Combination vs monotherapy for the treatment of community-acquired pneumonia: impact on medical outcomes.
- 2000-01 _____, Pharm IV. Ciprofloxacin-resistant *Pseudomonas aeruginosa*: risk for acquisition and impact on outcomes.
- _____ , Pharm IV. A Prospective evaluation of the barriers to receipt of pneumococcal and influenza vaccine in the elderly Asian immigrant population.
- 2001-02 _____, Pharm IV. Applying patient selection criteria for drotrecogin alfa therapy in practice.
- 2001-02 _____, Pharm IV. Antiretroviral drug resistance genotype testing at a hospital-based HIV-clinic: practice pattern and impact on outcome.
- 2003 _____, Pharm IV. Ciprofloxacin-resistant *Pseudomonas aeruginosa*: risks for acquisition and associated outcomes

Resident/Fellow Research Projects Supervised

- 1993-94 _____, Pharm.D.: Prospective Evaluation of Fluconazole Use and Outcomes at a Teaching Institution.
- 1996-97 _____, Pharm.D.: Treatment Outcomes of Bacteremia Caused by Extended-spectrum Beta-lactamase producing *E.coli* and *Klebsiella pneumoniae*.
- 1998-99 _____, Pharm.D.: Prospective comparison of patients hospitalized for community-acquired pneumonia with or without prior outpatient antibiotic therapy.
- 1999-00 _____, Pharm.D.: A Prospective evaluation of the factors associated with the receipt of pneumococcal vaccine in hospitalized elderly population.
- 2000-01 _____, Pharm.D.: Use of newer fluoroquinolones for gram-positive respiratory tract infections: is there a deleterious collateral effect on *Pseudomonas aeruginosa* susceptibility ?
- 2001-02 _____, Pharm.D.: Effect of Continuous Enteral Feeding on Pharmacokinetics of Oral Linezolid
- 2002-03 _____, Pharm.D.:
1. Prevalence of Efflux-mediated fluoroquinolone resistance in *Pseudomonas aeruginosa*
2. Prospective comparison of the effectiveness of cefotetan for the treatment of non-life threatening infections caused by *E. coli* with or without ESBL production
- 2003-04 _____, Pharm.D.: Health and economic outcome in the management of adults with invasive candidiasis: comparison of traditional and new antifungal agents.

_____, PharmD: Fluoroquinolone-resistant *E. coli*: molecular basis for resistance and clinical outcomes.
- 2003-05 _____, PharmD: Phenotypic markers and outcome correlation of efflux-mediated resistance in clinical isolates of *Pseudomonas aeruginosa*
- 2004-05 _____, PharmD: MRSA *agr* group II polymorphism: Identification, prevalence, and impact on vancomycin treatment outcomes
- 2005-06 _____, PharmD: Bacteriologic and Clinical Impact of Levofloxacin Deletion from the Formulary

PROFESSIONAL SERVICE

Institutional Committees:

University of Southern California – School of Pharmacy

2003-05 Intermodule Curriculum Committee – member as course coordinator
2005 Ad Hoc Committee on Case Conference - Chair
2004-06 Curriculum Committee – elected member
2004 Ad Hoc Committee on Ethical Conduct
2006 _____

Western University of Health Sciences - College of Pharmacy

1997 Pharmacy Practice Faculty Search Committee
1997-98 Academic Performance and Standards Committee
 Curriculum Committee
 Educational Resources Committee
1997-2000 _____
1998-99 Curriculum Committee
 Planning, Priorities, and Resource Committee
1999-00 Dean’s Council – elected faculty representative
 Ad Hoc Pharmacy Practice Faculty Search Committee, [Chair]
2000-01 Pharmacy Practice Scholarship Committee, [Chair]
 Ad Hoc Pharmacy Practice Faculty Search Committee
2001 Curriculum Committee
2001-02 Curriculum Committee
 Ad Hoc Pharmacy Practice Faculty Search Committee
 Ad Hoc Faculty Workload Committee [Chair]
2002-03 Curriculum Committee, [Vice Chair]
2001-2004 _____

Huntington Memorial Hospital - Pasadena, CA

1997-present Infection Control Committee
1999 Laboratory Liaison Committee

UCLA Medical Center

1993-96 Antibiotic Subcommittee - Pharmacy and Therapeutics Committee [Secretary]
1993-96 Infection Control Committee
1995-96 Critical Pathway Committee on Pneumonia -
1996-97 Antibiotic Resistance Working Group -

USC University Hospital

1992-93 Antibiotic Subcommittee - Pharmacy and Therapeutics Committee [Co-Chair]
1992-93 Infection Control Committee

PROFESSIONAL SERVICE (cont.)

Professional Organizations


- 1991-Present California Society of Health-System Pharmacists - Member
- 1991-Present American Society of Health-System Pharmacists - Member
- 1992-Present American Society of Microbiology - Member
- 1995-Present American College of Clinical Pharmacy - Member
- 1995-Present Southern California Society of Health-System Pharmacists - Member
- 1997-Present Southern California Chapter – ACCP
 - President Elect –2000
 - President –2001
 - Immediate Past President - 2002
- 1999-Present Society of Infectious Diseases Pharmacists
 - Publications Committee member – 1999-2000
- 1999-2000 AACP Faculty Delegate (elected Alternate)
- 1999 –2001 California Pharmaceutical Association
 - Regional Media Spokesperson for the Alliance Working for Antibiotic Resistance Education Group (2001)
- 2001 – Present American Pharmaceutical Association – Member
- 2001 – Present Infectious Diseases Society of America – Member

Governmental Organizations

- 1993 – 2001 California State Board of Pharmacy – Competency Committee, Appointed Member 8-year term
- 2006 FDA Anti-Infective Advisory Committee Member, nominated

Consultant Activity

Advisory Boards

- 1996-97
 - 1998
 - 1998
 - 2000
 - 2000, 2001, 2002
 - 2001
 - 2001
 - 2004
 - 2005
- 

Journal Referee

- 1993 - 1996 University Health-System Consortium Drug Monographs
- 1994 - 2002 *Annals of Pharmacotherapy*

1995 *Southern Medical Journal*
 Pharmacist Letter
1996 *Hospital Pharmacy*
1998 *Clinical Infectious Diseases*

Professional Organizations (cont.)

Journal Referee

1998 - Present *Pharmacotherapy*
1999 *J Pharmaceutical Sciences*
2001 *Pharmaceutical Research*
 Clinical Infectious Diseases
 Medical Mycology
2002 - Present *Pharmacotherapy*
2003 *Am J Health-System Pharm*
2005 *Chest*

INVITED PRESENTATIONS

Jan 1991 “Combination versus monotherapy for the treatment of *Pseudomonas* infections.”
Pharmacy Grand Rounds, Division of Clinical Pharmacy, University of California
Medical Center, San Francisco.

Mar 1993 “Diabetes and Patient Education. Pathophysiology of Diabetes Mellitus”
California Pharmacists Association. Burlingame, CA. [1 ACPE credit]

Mar 1994 “Beta-lactamases and enzyme Inhibitors” Staff Development Series, UCLA
Department of Pharmaceutical Services, Los Angeles, CA.

April 1994 “Outpatient Use of Antibiotics” Dermatology Grand Rounds, UCLA Medical
Center, Los Angeles, CA. [1 CME credit]

May 1994 “Use of Antibiotics in the Intensive Care Settings” Pulmonary/ICU Weekly
Conference, UCLA Medical Center, Los Angeles, CA.

Aug 1994 “Pharmacology on Anti-Infectives: Respiratory and Urinary Tract Infections”
Nursing Pharmacology Seminar, UCLA, School of Nursing, Los Angeles, CA.

Oct 1994 “Pharmacology on Anti-Infectives: Sexually Transmitted Diseases” Nursing
Pharmacology Seminar, UCLA, School of Nursing, Los Angeles, CA.

Jul 1995 “Antibiotic Control Program - Update” Staff Development Series. Department of
Pharmaceutical Services, UCLA Medical Center, Los Angeles, CA.

Sep 1995 “Ciprofloxacin - Clinical Case Conference” Staff Development Series,
Department of Pharmaceutical Services, UCLA Medical Center, Los Angeles,
CA.

- Nov 1995 “*Pharmacology of Antifungal and Antiviral Agents*” Post Master’s Nurse Practitioner Program, UCLA, School of Nursing, Los Angeles, CA.
- Jan 1996 “*Once-daily aminoglycosides: are we ready?*” Staff Development Series, Department of Pharmaceutical Services, UCLA Medical Center, Los Angeles, CA.
- Jun 1996 “*Antifungal Therapies in the 1990s - Pathogens, Treatment and Problems*” Southern California Society of Health-System Pharmacists, Los Angeles, CA. [1 AES credit]
- “*Antifungal Therapies in the 1990s - Pathogens, Treatment and Problems*” Staff Development Series, Department of Pharmaceutical Services, UCLA Medical Center, Los Angeles, CA.
- Aug 1996 “*Clinical Pearls on the Practice of Infectious Diseases*” Staff Development Series, Department of Pharmaceutical Services, UCLA Medical Center, Los Angeles, CA.
- Oct 1996 “*Role of the Infectious Diseases Pharmacist in Therapy*” Microbiology and Immunology 201 - Fall 1996, UCLA School of Medicine, Los Angeles, CA.
- Oct 1996 “*Treatment of fungal infections: role of Amphotericin B Lipid Complex*” Medicine/Infectious Diseases Grand Rounds, UCLA Medical Center, Los Angeles, CA. [1 CME credit]
- “*Antifungal Therapies: new agents and future directions*” Symposium: Update on Fungal Infections, Bay Area Society of Infectious Diseases Physician - Northern California.[1 CME credit]
- Mar 1997 “*Beta-lactamases and Therapeutic Implications*” Department of Pharmacy, Staff Development, Huntington Memorial Hospital, Pasadena, CA.
- April 1997 “*Treatment of Common Infections in Patients with Diabetes*” Pre-symposium: Update on Diabetes Therapy, Focus '97 - CSHP, Universal Studios, CA.[1 ACPE credit]
- “*Treatment of Common Infections in Patients with Diabetes*” California Society of Health-Systems Pharmacists (San Gabriel Valley and Southern California Chapters) and Nevada Society of Health-Systems Pharmacists, Las Vegas, Nevada. [1 AES credit]
- Jul 1997 “*Current Status of Antifungal Therapies*” Orange County Society of Health System Pharmacists, Fullerton, CA. [1 AES credit]
- Aug 1997 “*Update on Antifungal Therapies*” Department of Pharmacy, Staff Development, Huntington Memorial Hospital, Pasadena, CA.

- Oct 1997 “*Antibacterials: New versus Old*” Department of Pharmacy, Staff Development, Huntington Memorial Hospital, Pasadena, CA.
- Jan 1998 “*Liposome Technology: Application to Antifungal Therapies*” Bay Area Vascular Access Network, San Francisco, CA. [1 Nursing CE]
- Mar 1998 “*Clinical Perspective on New Antibiotics*” Southern California Chapter – American Society of Microbiology, Los Angeles and San Diego, CA. [1 CEU]
- “*Economic Aspects of Antibacterial Adverse Effects*” Spring Symposium – Infectious Diseases of the 1990’s: Challenges and Solutions. San Francisco, CA.
- Aug 1998 “*Infections in the Elderly: pneumonia and UTIs*” Geriatric Pharmacy Mini-Residency Program: Therapeutic Assessment and Implementation, Western University of Health Sciences, College of Pharmacy. Pomona, CA. [1 ACPE credit]
- Oct 1998 “*Clinical Pearls: Antimicrobial Resistance*” CSHP – Seminar ’98, Anaheim, CA. [2 ACPE credit]
- Nov 1998 “*Gram-negative Bacteria: Focus on Beta-lactam Resistance*” Inland Society of Health-system Pharmacists, Ontario, CA. [1 AES credit]
- Feb 1999 “*Antimicrobial Update: When to use what in hospitalized patients*” Huntington Memorial Hospital Medical Housestaff Noon Conference, Pasadena, CA.
- April 1999 “*Women & Men’s Health Issues in the 21st Century: Sexually Transmitted Disease (STD) – Drugs of Choice for Best Therapeutic Outcomes*” SCSHP/OCSHP/SFVSHP, Anaheim, CA. [1 AES credit]
- April 1999 “*Antimicrobial Utilization Trends: Impact on Bacterial Resistance*” Wyeth-Ayerst Lederle, Arcadia, CA.
- July 1999 “*Antimicrobial Use and Resistance*” Association for Professionals in Infection Control Greater Los Angeles Chapter, Los Angeles, CA. [1 CEU]
- Oct 1999 “*Antifungal Therapy: New Agents and New Directions*” CSHP – Seminar ’99, Long Beach, CA. [1 ACPE credit]
- Nov 1999 “*Use of Laboratory Report in Empirical and Directed Therapy for Infectious Diseases*” American Society of Microbiology Southern California Branch, Irvine, CA. [1 CEU]
- Nov 1999 “*ESBL-Producing E.coli and Kleb. pneumoniae: Clinical and Therapeutic Implications*” American College of Clinical Pharmacy Southern California Chapter, Costa Mesa, CA. [1 ACPE credit]

- Mar 2000 “*Gram-Negative Bacterial Resistance*” CSHP-Focus 2000 Symposium, Oakland, CA [1 CEU].
- Oct 2000 “*Overview and Update on Antibiotics*” CpHA Education Faire 2000, Pasadena, CA [2 CEU].
- Nov 2000 “*Antimicrobial Therapy in the era of Resistance*” Huntington Memorial Staff Development Series, Pasadena, CA [1 CEU].
- Nov 2000 “*IV to PO Antibiotic Switch*” Huntington Memorial Housestaff Noon Conference, Pasadena, CA.
- Nov 2000 “*Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)*” Emerging Pathogens and Interventions for Clinicians, Boca Raton, Florida [1 CEU each].
- Mar 2001 “*Novel Agents for the Treatment of Bacterial Infections*” CSHP-Focus 2001 Pre-symposium, Pasadena, CA [1 CEU].
- Mar 2001 “*Antimicrobial Resistance*” CSHP-Focus 2001, Pasadena, CA, [1CEU].
- “*Update on Antifungal Therapy*” CSHP-Focus 2001, Pasadena, CA. [1CEU].
- May 2001 “*Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)*” Emerging Pathogens and Interventions for Clinicians, Los Angeles [1 CEU].
- June 2001 “*Antimicrobial Resistance in the Intensive Care Unit*” Sharp Health Care Systems: Critical Care Conference, San Diego, CA. [1 CEU]
- “*Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)*” Emerging Pathogens and Interventions for Clinicians, San Francisco. [1 CEU]
- Oct 2001 “*Antimicrobial Resistance*” Daniel Freeman Memorial Medical Center – Continuing Education Development Day, Los Angeles. [1 CEU]
- Nov 2001 “*Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)*” Emerging Pathogens and Interventions for Clinicians, Seattle. [1 CEU]
- Feb 2002 “*Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)*” Emerging Pathogens and Interventions for Clinicians, Loma Linda University Medical Center Internal Medicine Housestaff Noon Conference. [1 CEU]

- Feb 2002 “Antimicrobial Resistance” Huntington Memorial Hospital – Internal Medicine Housestaff Noon Conference. [1 CME]
- Mar 2002 “Multi-drug Resistance in Gram-negative Bacteria that Produce Extended-spectrum B-lactamases (ESBLs)” Daniel Freeman Marina Hospital – Medical Grand Rounds. [1 CME]
- Apr 2002 “Antimicrobial Resistance” Doctors Hospital Montclair – Medical Grand Rounds [1 CME]
- June 2002 “Antimicrobial Resistance” Glendale Adventist Medical Center – Medical Grand Rounds [1 CME]
- Feb 2003 “Antimicrobial Resistance” Verdugo Hills Medical Center – Medical Grand Rounds [1 CME]
- April 2003 “Antimicrobial Resistance” Midway Hospital – Medical Grand Rounds [1 CME]
- April 2003 “Antimicrobial Resistance” San Bernardino County Osteopathic Medical Association.
- May 2003 “Update on Antifungal Therapy” Huntington Memorial Hospital – Internal Medicine Housestaff Noon Conference. [1 CME]
- July 2003 “Antimicrobial Resistance” Hubert Humphrey Comprehensive Health Center – Medical Grand Rounds. [1 CME]
- Nov 2003 “Antimicrobial Resistance” Northridge Medical Center – Medical Grand Rounds. [1 CME]
- Dec 2003 “Update on the Management of Community-Acquired Pneumonia” Huntington Hospital – Internal Medicine Housestaff Noon Conference. [1 CME]
- Mar 2004 “Antimicrobial Resistance” Huntington Hospital – Internal Medicine Housestaff Noon Conference. [1 CME]
- May 2004 “Antimicrobial Resistance” Children’s Hospital Los Angeles – Pharmacy Noon Conference.
- June 2004 “Update on Antifungal Therapy” City of Hope 12th Annual Conference on Rational Therapeutics. [1 CEU]
- Sep 2004 “Antimicrobial Resistance” Hoag Memorial Hospital – Pharmacy Staff Conference.
- Oct 2004 “Antimicrobial Resistance” Cedars Sinai Medical Center – Pharmacy Grand Rounds. [1 CEU]

- Mar 2005 "Antimicrobial Resistance" Huntington Hospital – Internal Medicine Housestaff Noon Conference. [1 CME]
- Mar 2005 "Hospital-acquired pneumonia" Daniel Freeman Memorial Hospital – Primary Care Physician Network.
- Mar 2005 "MRSA Infections: Update" – King Drew Medical Center, Internal Medicine Noon Conference. [1 CME]
- July 2005 "Fluoroquinolone resistance affects virulence in *Pseudomonas aeruginosa*" Pulmonary Grand Rounds, UCSF Medical Center.
- Mar 2006 "Update on Antimicrobial Resistance" – Huntington Hospital, Internal Medicine Noon Conference. [1 CME]
- Mar 2006 "Fluoroquinolone Use: Impact on bacterial resistance and virulence" Pulmonary Conference, USC Adult Cystic Fibrosis Center.

SCHOLARLY ACTIVITY

Research Grant Information

Title: Treatment outcome of extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bacteremia: correlation of treatment outcomes with microbiologic and molecular analysis"

Role: Principal Investigator

Funding & Source: \$ _____

Status: Not approved 1997; study completed

Title: Prevalence, antifungal susceptibilities, and treatment outcome of infections due to non-*albicans Candida* species among hospitalized patients

Role: Principal Investigator

Funding & Source: \$ _____

Status: Approved September 1997; study completed

Title: A prospective comparison of patients hospitalized for community-acquired pneumonia with or without prior outpatient antibiotic therapy

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved December 1998; study completed.

Title: A Pharmacy-based intervention program to increase pneumococcal and influenza vaccination rates among elderly hospitalized patients

Role: Principal Investigator

Funding & Source: \$ _____ ASHP Foundation

Status: Not approved 1999

Title: A Prospective Evaluation of the Factors Associated with the Receipt of Pneumococcal Vaccine in Hospitalized Elderly Population.

Role: Principal Investigator 1999-2000.

Title: A Prospective Evaluation of the Barriers to Receipt of Pneumococcal and Influenza Vaccine in the Elderly Asian Immigrant Population.

Role: Principal Investigator

Funding & Source: \$ _____; Western University Intramural Research Award

Status: approved December 1999; study completed

Title: Combination vs Monotherapy for the treatment of community-acquired pneumonia: impact on medical outcomes

Role: Principal Investigator

Funding & Source: \$ _____

Status: not approved 2000; study completed.

Title: Use of newer fluoroquinolones for gram-positive respiratory tract infections: is there a deleterious collateral effect on *Pseudomonas aeruginosa* susceptibility?"

Role: Principal Investigator

Funding & Source: \$ _____

Status: not approved 2000; study completed

Title: Effect of Continuous Enteral Feeding on Pharmacokinetics of Oral _____

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved December 2000; study completed.

Title: Evaluation of the Aerosolization Potential of Antifungal Agents

Role: Principal Investigator

Funding & Source: \$ _____, Western University Intramural Research Award

Status: approved January 2001.

Title: Comparison of the Aerosolization Potential of _____ versus _____

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved May 2001; study completed.

Title: Prevalence of Efflux-mediated resistance among clinical isolates of *Pseudomonas aeruginosa*.

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved May 2002, November 2001; study completed.

Title: Prospective Comparison of the effectiveness of _____ for the treatment of non-life threatening infections caused by *E coli* with or without ESBL production

Role: Principal Investigator

Funding & Source: \$ _____

Status: not approved 2003; study discontinued due to low patient enrollment.

Title: Health and economic outcome of adult patients treated for invasive candidiasis: comparison of traditional versus new antifungal agents

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved Jan 2004

Title: MRSA *agr* group II polymorphism: Identification, prevalence, and impact on vancomycin treatment outcomes

Role: Principal Investigator

Funding & Source: \$ _____

Status: approved Jan 2005

Title: Role of biofilm on antibiotic-induced virulence in *P. aeruginosa*

Role: Subcontract (PI)

Funding & Source: \$306,195 NIH

Status: pending review, submitted Feb 1, 2006

Title: Fluoroquinolone resistance affects *P. aeruginosa* virulence

Role: Principal Investigator

Funding & Source: \$ _____ ACCP Frontiers Investigator Award

Status: pending review, submitted April 3, 2006

Publications

Peer-Reviewed:

1. **Wong-Beringer A**, Jacobs RA, Guglielmo BJ. Treatment of funguria. *JAMA*. 1992;267:2780-2785.
2. **Wong-Beringer A**, Jacobs RA, Guglielmo BJ. Nosocomial funguria: resultant morbidity and therapeutic intervention (letter). *Clin Infect Dis* 1993;17:1066-7.
3. Guglielmo BJ, **Wong-Beringer A**, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. *Bone Marrow Transplant* 1994;13:499-510.
4. **Wong-Beringer A**, Corelli R, Schrock T, Guglielmo BJ. Influence of timing of antibiotic administration on tissue concentrations during surgery. *Am J Surg* 1995;169:379-381.

5. **Wong-Beringer A**, Beringer PM, Rho J. Focus on amphotericin lipid complex (ABLC): a novel antifungal agent. *Formulary* 1996;31:169-185.
6. Sievers T, Kubak B, **Wong-Beringer A**. Safety and efficacy of Intralipid emulsions of amphotericin B. *J Antimicrob Chemother* 1996;38:333-47.
7. **Wong-Beringer A**. Criteria for use of amphotericin B lipid complex in adult and pediatric patients. *Am J Health-System Pharm* 1996;53:2751-2.
8. **Wong-Beringer A**, Beringer PM, Lovett MA. Successful treatment of meningitis due to multi-drug resistant *Pseudomonas aeruginosa* with high-dose ciprofloxacin therapy. *Clin Infect Dis* 1997;25:936-7.
9. Beringer PM, **Wong-Beringer A**, Rho JP. Economic aspects of antibacterial adverse effects. *Pharmacoeconomics* 1998;13:35-49.
10. Beringer PM, **Wong-Beringer A**, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. *Ann Pharmacother* 1998;32:176-81.
11. **Wong-Beringer A**, Jacobs RA, Guglielmo BJ. Lipid-formulated amphotericin B: clinical efficacy and toxicities. *Clinical Infectious Diseases* 1998;27:608-18.
12. **Wong-Beringer A**. Empirical antimicrobial prescribing practices: impact on outcome and cost. *Hospital Pharmacy* 1998;33:1208-1213.
13. **Wong-Beringer A**, Shriner K. Fluconazole-induced agranulocytosis with eosinophilia. *Pharmacotherapy* 2000;20(4):484-6.
14. **Wong-Beringer A**, Lee NP, Hindler JA, Steele-Moore L. Clinical applicability of antifungal susceptibility testing on non-*Candida albicans* species in hospitalized patients. *Diagn Microbiol Infect Dis* 2001;39:25-31.
15. **Wong-Beringer A**. Extended-spectrum B-lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae*: clinical and therapeutic implications. *Pharmacotherapy* 2001;21:583-92.
16. **Wong-Beringer A**, Nguyen KH, Razeghi J. Implementing an IV to PO switch program: one center's experience. *Am J Health-System Pharm* 2001;58:1146-9.
17. **Wong-Beringer A**, Hindler J, Loeloff M, Queenan AM, Lee NP, Pegues DA, Quinn JP, Bush K. Molecular correlation for the treatment outcomes in bloodstream infections caused by *Escherichia coli* and *Klebsiella pneumoniae* with reduced susceptibility to ceftazidime. *Clin Infect Dis* 2002;34:135-146.
18. **Wong-Beringer A**, Brodetsky E, Quist R. Pneumococcal vaccination in the hospitalized elderly patients: areas for pharmacist involvement. *Pharmacotherapy* 2003;2:199-208.

19. **Wong-Beringer A**, Liao C, Nguyen M, Pallares J. Applying patient selection criteria for drotrecogin alfa therapy in practice. *Am J Health System Pharm* 2003;60:1345-52.
20. **Wong-Beringer A**, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. *Pharmacotherapy* 2003;23:1441-1462.
21. Lee J, **Wong-Beringer A**. Persistent *Bacillus cereus* bacteremia in an immunocompetent host. *Infect Dis Clin Practice* 2004;12:1-3.
22. Lynch J, **Wong-Beringer A**. Caspofungin-induced severe reversible thrombocytopenia. *Pharmacotherapy* 2004;24:1408-11.
23. **Wong-Beringer A**. Treatment of Serious Infections – focus on cefepime. *Pharmacotherapy* 2004 December supplement
24. Hsu D, Okamoto M, Murthy R, **Wong-Beringer A**. Fluoroquinolone-resistant *Pseudomonas aeruginosa*: risks for acquisition and associated outcomes. *J Antimicrob Chemother* 2005; 55:535-541.
25. Kriengkauykiat J, Porter E, Lomovskaya O, **Wong-Beringer A**. Use of an efflux-pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2005;49:565-570.
26. Beringer PM, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, **Wong-Beringer A**. Population pharmacokinetic analysis to evaluate the impact of continuous enteral feedings on the bioavailability of linezolid in hospitalized patients. *Antimicrob Agents Chemother* 2005;49:3676-81.
27. **Wong-Beringer A**, Lambros M, Beringer PM, Johnson D. Suitability of inhaled caspofungin for prevention of pulmonary aspergillosis: physicochemical profiling and nebulizer choice. *Chest* 2005;128:3711-16.

Book Chapters:

- Healy D, **Wong-Beringer A**. Endocarditis. In: Young LY, Koda-Kimble MA, eds. *Applied therapeutics: the clinical use of drugs*. 6th ed. Vancouver: *Applied Therapeutics*, 1995;(57)1-23.
- Wong-Beringer A**. Mycotic Infections. In: Herfindal ET, Gourley R. eds. *Textbook of Therapeutics: Drug and Disease management*. 7th ed. Lippincott, Williams and Wilkins 2000.
- Wong-Beringer A**. Endocarditis. In: Young LY, Koda-Kimble MA, eds. *Applied therapeutics: the clinical use of drugs*. 7th ed. Baltimore: Lippincott, Williams & Wilkins, 2001.

Wong-Beringer A. Endocarditis. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 8th ed. Baltimore: Lippincott, Williams & Wilkins, 2004.

Wong-Beringer A. Mycotic Infections. In: Herfindal ET, Gourley R. eds. *Textbook of Therapeutics: Drug and Disease management*. 8th ed. Lippincott, Williams and Wilkins 2006. (Submitted)

Non-Peer-Reviewed:

Wong-Beringer A. Basic Bibliography - Infectious Disease: Skin and Soft Tissue. *Hospital Pharmacy* 1995;30:545-546.

Louie SG, **Wong-Beringer A**, Sokolskiy L, Rho JP. Use of liposomes as drug carriers for chemotherapeutic and antifungal agents. *Calif J Health-System Pharm* 1996;8(6):9-14.

Wong-Beringer A. Implications of fluoroquinolones in various health care settings. In: North DS, ed. 31st Annual American Society of Health-System Pharmacists Midyear Clinical Meeting - New Orleans, Louisiana, December 1996. Med/Pharm Forum, June

Wong-Beringer A. Counseling and treating women with vulvovaginal candidiasis. *Medical Economics* 1996.

Wong-Beringer A. Antibiotic Hematologic Reactions. *Antibiotics for the Clinician* 1997.
Wong-Beringer A. Antimicrobial-resistant *Streptococcus pneumoniae*. Huntington Memorial Hospital Medical Staff Newsletter. Aug 1997.

Wong-Beringer A. Gram-negative bacteria: focus on beta-lactam resistance. *Calif J Health-System Pharm* 1998;10:14-18.

Wong-Beringer A. Emerging antibiotic-resistant mutants of *Escherichia coli* and *Klebsiella pneumoniae*: clinical and therapeutic implications. Huntington Memorial Hospital Medical Staff Newsletter. June 1999.

Wong-Beringer A. Levofloxacin usage evaluation: target areas for medication use improvement. Huntington Memorial Hospital Medical Staff Newsletter, January 2000.

Wong-Beringer A. Extended-spectrum B-lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae*: clinical and therapeutic implications. Society of Infectious Diseases Pharmacist Newsletter. Spring 2000.

Wong-Beringer A, Wallace S. Antimicrobial resistance on the rise at HMH. Huntington Memorial Hospital Medical Staff Newsletter. September and October 2000.

Non-Peer-Reviewed: (cont.)

Wong-Beringer A, Nguyen KH. A pocket guide PO alternatives to IV antibiotics. Huntington Memorial Hospital, version 2000.

Wong-Beringer A. Changing antimicrobial susceptibility at HMH. Huntington Memorial Hospital Medical Staff Newsletter. March 2002.

Wong-Beringer A. An evolving guideline for the treatment of community-acquired pneumonia. Huntington Memorial Hospital Medical Staff Newsletter. Jan 2003.

Lee J, **Wong-Beringer A.** Treatment options for MRSA infections based on HMH antibiogram. Huntington Memorial Hospital Medical Staff Newsletter. Jan 2004

Abstracts

Wong-Beringer A, Jacobs RA, Guglielmo BJ. Nosocomial funguria: resultant morbidity and therapeutic intervention. 11th Annual Western States Conference for Pharmacy Residents and Preceptors. Asilomar, California, April 1991. (Platform)

Wong-Beringer A, Jacobs RA, Guglielmo BJ. Nosocomial funguria: resultant morbidity and therapeutic intervention. American Society of Hospital Pharmacists, Midyear Clinical Meeting, New Orleans, December 1991. (Platform)

Wong-Beringer A, Corelli R, Schrock T, Guglielmo BJ. The influence of timing of antibiotic administration on tissue concentrations during surgery. 12th Annual Western States Conference for Pharmacy Residents and Preceptors. Asilomar, California, May 1992. (Platform)

Wong-Beringer A, Corelli R, Schrock T, Guglielmo BJ. The influence of timing of antibiotic administration on tissue concentrations during surgery. American Society of Hospital Pharmacists, Midyear Clinical Meeting, Orlando, December 1992. (Platform)

Kubak BM, **Wong-Beringer A, Holt CD, Waters P, Levine MS, Shpiner RA.** Infection surveillance and prophylaxis in lung transplantation. Lung Transplantation: An International Dialogue, Laguna Beach, California. January 1995. (Platform)

Dishon M, Corelli R, Glick M, **Wong-Beringer A, Guglielmo BJ.** A comparison of differing antibiotic review systems in controlling the use of intravenous ciprofloxacin. Western States Conference, Asilomar, California. May 1995. (Platform)

Wong-Beringer A, Yun S. A prospective analysis of fluconazole use and treatment outcome at a university teaching hospital. California Society of Health-System Pharmacists, Annual Meeting, Palm Springs, California. October 1995. (Poster)

Beringer PM, **Wong-Beringer A**, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. 1996 Annual Meeting American College of Clinical Pharmacy. Nashville, Tennessee. August 4-7, 1996. (Platform)

Lee NP, **Wong-Beringer A**, Pegues DA. Ceftazidime-resistant *Escherichia coli* and *Klebsiella pneumoniae* bacteremia. Western States Conference, Asilomar, California 1997. (Platform)

Wong-Beringer A, Lee NP, Hindler J, Pegues DA. Treatment outcome of ESBL-producing *Escherichia coli* (EC) and *Klebsiella pneumoniae* (KP) Bacteremia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28, 1997. (Poster)

Hindler JA, Setiawan W, **Wong-Beringer A**, Kelkar BS, Bush K, Quinn JP. Phenotypic variability among blood isolates of *Escherichia coli* (EC) and *Klebsiella pneumoniae* (KP) with reduced susceptibility to ceftazidime (CTAZ). 1998 American Society of Microbiology, Atlanta, May 1998. (Poster)

Nguyen KH, **Wong-Beringer A**. "A prospective evaluation of levofloxacin use at a community teaching hospital" CSHP-Seminar '99, Long Beach, October 15, 1999 (Poster)

Sadeghi M, Gurevitch MJ, **Wong-Beringer A**. "Prospective evaluation of risk factors leading to hospitalization of patients who failed initial treatment for community-acquired pneumonia" Western States conference, Asilomar, California, May 1999. (Platform)

Wong-Beringer A, Lee NP, Hindler JA, Bush K. "Clinical Outcome of Patients with Extended-Spectrum β -lactamase (ESBL)-Producing *Klebsiella pneumoniae* and *Escherichia coli* Bacteremia After Treatment with Expanded Spectrum Cephalosporins" 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 28, 1999 (Poster)

Wong-Beringer A, Sadeghi M. "A prospective comparison of patients hospitalized for community-acquired pneumonia with or without prior outpatient antibiotic therapy" ACCP 2000 Spring Practice and Research Forum, Monterey, California, April 6, 2000. (Poster)

Wong-Beringer A, Lee NP, Hindler JA, Bush K. "Clinical Outcome of Patients with Extended-Spectrum β -Lactamase (ESBL)-Producing *Klebsiella pneumoniae* and *Escherichia coli* Bacteremia After Treatment with Expanded Spectrum Cephalosporins" ACCP 2000 Spring Practice and Research Forum, Monterey, California, April 6, 2000. (Poster)

Brodetsky E, **Wong-Beringer A**. "A Prospective Evaluation of the Factors Associated with the Receipt of Pneumococcal Vaccine in Hospitalized Elderly Population." Western States conference, Asilomar, California, May 2000. (Platform)

Abstracts (cont.)

Brodetsky E, **Wong-Beringer A.** "A Prospective Evaluation of the Factors Associated with the Receipt of Pneumococcal Vaccine in Hospitalized Elderly Population." ACCP 2000 Annual Meeting, Los Angeles, California, November 6, 2000. (Platform)

Tong T, Phung S, **Wong-Beringer A.** "Combination vs Monotherapy for the treatment of community-acquired pneumonia: impact on medical outcomes" ACCP 2000 Annual Meeting, Los Angeles, California, November 6, 2000. (Poster)

Razeghi J, Okamoto M, **Wong-Beringer A.** "Use of newer fluoroquinolones for gram-positive respiratory tract infections: is there a deleterious collateral effect on *Pseudomonas aeruginosa* susceptibility?" Western States Conference, Asilomar, California, May 2001. (Platform)

Razeghi J, Sun Joo Kim, **Wong-Beringer A.** "*Ciprofloxacin-resistant Pseudomonas aeruginosa: impact on outcomes*" Infectious Diseases Society of America Annual Meeting, San Francisco, October 2001. (Poster)

M Nguyen, P Beringer, **A Wong-Beringer**, S Louie, M Gill, MA Gurevitch. "Effect of Continuous Enteral Feedings (TF) on Oral Bioavailability (F) of Linezolid (LZD) in Hospitalized Patients" Abstract A-1614. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2003. (Poster)

A Wong-Beringer, MP Lambros, DL Johnson. "Aerosolization of caspofungin" Abstract M-1258. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2003. (Poster)

A Wong-Beringer, C Flores, JA Hindler "Variable Inoculum Effect (IE) and Predictability of Extended-Spectrum Cephalosporin (ESC) MICs on Treatment Outcome in *E. coli* (EC) and *K. pneumoniae* (KP) Isolates with Ceftazidime-resistance (CAZ-R) Causing Bloodstream Infections" Abstract D-208. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2003. (Poster)

J Kriengkauykiat, **A Wong-Beringer**, E Porter. "Use of an Efflux Pump Inhibitor (EPI) to Determine Efflux Pump (EP)-Mediated Fluoroquinolone Resistance (FQ-R) in *Pseudomonas aeruginosa* (PA)" Abstract D-245. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2003. (Poster)

D Hsu, **A Wong-Beringer**, M Okamoto "Ciprofloxacin-resistant *Pseudomonas aeruginosa*: risks for acquisition and associated outcomes" 41st Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, October, 2003. (Poster)

J Lee, **A Wong-Beringer**. 44th "Ciprofloxacin-resistant *E. coli* and *P. mirabilis*: Epidemiology & Outcomes" Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October, 2004. (Poster)

A Wong-Beringer, MP Lambros, DL Johnson. "Aerosolization Potential of amphotericin B lipid complex". 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October, 2004. (Poster)

A Wong-Beringer, J Flanagan, J Wiener-Kronish. "Fluoroquinolone resistance is Associated with increased type III secretion virulence in clinical isolates of *Pseudomonas aeruginosa*." 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December, 2005. (Platform)

J Kriengkauykiat, M. Kadono, N. Gotoh, E Porter, T Synold, **A Wong-Beringer**. "Combined efflux pump overexpression and gyrase A mutation causes levofloxacin resistance in clinical isolates of *Pseudomonas aeruginosa*" 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December, 2005. (Poster)

D Hsu, L Hidayat, K Shriner, **A Wong-Beringer**. "Correlation of vancomycin minimum inhibitory concentration using VITEK versus E test with treatment outcomes of methicillin-resistant *Staphylococcus aureus* (MRSA) infections" 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December, 2005. (Poster)

Hidayat L, D Hsu, K SHRiner, **A Wong-Beringer**. "Outcomes of vancomycin (VAN) - treated methicillin-resistant *Staphylococcus aureus* (MRSA) infections targeting higher trough (Tr) concentration" 45th Infectious Diseases Society of America (IDSA), San Francisco, October 2005. (Poster)

**APPEARS THIS WAY
ON ORIGINAL**